U.S. specialty drug company Pozen Inc. announced Monday that it plans to acquire Tribute Pharmaceuticals Canada in a deal valued at about US$146 million. After the acquisition, expected to be competed in the fourth quarter, the combined company will change its name to Aralez Pharmaceuticals PLC and move its headquarters to Ireland to benefit from lower corporate tax rates in that country.